Sonoma Pharmaceuticals (SNOA) Times Interest Earned (2010 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Times Interest Earned came in at $87.75 in Q1 2026, up 140.13% year-on-year from $36.54 in Q1 2025, and up 255.31% quarter-over-quarter from -$56.5 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Times Interest Earned (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Times Interest Earned history runs 17 years deep, the most recent figure standing at $87.75 for Q1 2026.
- On a quarterly basis, Times Interest Earned rose 140.13% year-over-year to $87.75 in Q1 2026; TTM through Mar 2026 was -$410.17, a 65.84% decrease from a year earlier, with the FY2026 full-year figure at -$0.09, up 27.39% from the prior year.
- Times Interest Earned improved to $87.75 in Q1 2026 per SNOA's latest filing, from -$56.5 in the prior quarter.
- Across five years, Times Interest Earned topped out at $87.75 in Q1 2026 and bottomed at -$255.0 in Q1 2022.
- The 5-year median for Times Interest Earned is -$15.14 (2023), against an average of -$62.67.
- Across the five-year window, Times Interest Earned sank 1750.85% in 2023 and surged 140.13% in 2026, its largest moves.
- Year by year, Times Interest Earned stood at -$3.43 in 2022, then sank by 622.78% to -$24.82 in 2023, then jumped by 80.65% to -$4.8 in 2024, then slumped by 1076.53% to -$56.5 in 2025, then jumped by 255.31% to $87.75 in 2026.
- Per Business Quant, the three latest SNOA Times Interest Earned figures stand at $87.75 (Q1 2026), -$56.5 (Q4 2025), and -$2.59 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | 87.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.75 |
| Dec 31, 2025 | -56.50 |
| Sep 30, 2025 | -2.59 |
| Jun 30, 2025 | -5.45 |
| Mar 31, 2025 | -218.67 |
| Sep 30, 2024 | -4.80 |
| Jun 30, 2024 | -48.88 |
| Mar 31, 2024 | -201.29 |
| Dec 31, 2023 | -24.82 |
| Sep 30, 2023 | -3.09 |
| Jun 30, 2023 | -29.52 |
| Mar 31, 2023 | -229.40 |
| Dec 31, 2022 | -3.43 |
| Sep 30, 2022 | -5.41 |
| Jun 30, 2022 | -1.60 |
| Mar 31, 2022 | -255.00 |
| Dec 31, 2021 | -68.43 |
| Sep 30, 2021 | -1.23 |
| Jun 30, 2021 | -1.13 |
| Dec 31, 2020 | -0.47 |